Published in Am J Public Health on November 12, 2009
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Stigma and racial/ethnic HIV disparities: moving toward resilience. Am Psychol (2013) 1.93
Text messaging for enhancement of testing and treatment for tuberculosis, human immunodeficiency virus, and syphilis: a survey of attitudes toward cellular phones and healthcare. Telemed J E Health (2011) 1.61
Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006. South Med J (2011) 1.52
An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urban Health (2011) 1.48
Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002-2008). Med Care (2012) 1.28
High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr (2013) 1.23
Linking HIV-positive adolescents to care in 15 different clinics across the United States: creating solutions to address structural barriers for linkage to care. AIDS Care (2013) 1.17
Use of and Adherence to Antiretroviral Therapy in a Large U.S. Sample of HIV-infected Adults in Care, 2007-2008. Open AIDS J (2012) 1.11
Perceived discrimination and physical health among HIV-positive Black and Latino men who have sex with men. AIDS Behav (2013) 1.05
Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J (2013) 1.01
Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network. J Acquir Immune Defic Syndr (2011) 1.01
The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr (2011) 0.98
Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr (2013) 0.96
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
Multi-dimensional risk factor patterns associated with non-use of highly active antiretroviral therapy among human immunodeficiency virus-infected women. Womens Health Issues (2010) 0.89
Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care. AIDS Patient Care STDS (2012) 0.87
Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend (2014) 0.80
Effects of Lifetime History of Use of Problematic Alcohol on HIV Medication Adherence. J Int Assoc Provid AIDS Care (2013) 0.79
Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.78
Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009. J Acquir Immune Defic Syndr (2016) 0.75
The state of disparities in opportunistic infection prophylaxis for blacks with HIV/AIDS. Med Care (2012) 0.75
Creating Systems Change to Support Goals for HIV Continuum of Care: The Role of Community Coalitions to Reduce Structural Barriers for Adolescents and Young Adults. J HIV AIDS Soc Serv (2016) 0.75
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies. Open Forum Infect Dis (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA (1999) 10.93
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr (2000) 2.60
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15
Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making (2001) 1.97
What is moderate drinking? Defining "drinks" and drinking levels. Alcohol Res Health (1999) 1.82
Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. J Gen Intern Med (2001) 1.74
Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr (2000) 1.69
Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health (2007) 1.68
Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health (2002) 1.41
Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend (2007) 1.28
Longitudinal relationships between use of highly active antiretroviral therapy and satisfaction with care among women living with HIV/AIDS. Am J Public Health (2006) 1.01
Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am J Public Health (2001) 0.94
Combination antiretroviral therapy: health care providers confront emerging dilemmas. AIDS Care (2000) 0.92
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2009) 3.52
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis (2004) 3.17
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Rapid HIV-1 testing during labor: a multicenter study. JAMA (2004) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Recommendations for teaching about racial and ethnic disparities in health and health care. Ann Intern Med (2007) 2.50
Measuring retention in HIV care: the elusive gold standard. J Acquir Immune Defic Syndr (2012) 2.47
Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr (2002) 2.30
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2004) 2.17
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
HIV/AIDS: a minority health issue. Med Clin North Am (2005) 1.96
Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr (2003) 1.95
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr (2009) 1.73
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis (2006) 1.61
Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J Clin Microbiol (2005) 1.60
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2004) 1.58
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend (2007) 1.50
Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend (2007) 1.50
Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause (2015) 1.49
Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol (2007) 1.48
Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS (2015) 1.47
Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis (2002) 1.46
Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS (2005) 1.42
A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis (2012) 1.42
Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer (2009) 1.42
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
The body-inversion effect. Psychol Sci (2003) 1.38
Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (2010) 1.37
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS Behav (2007) 1.31
Obesity and immune cell counts in women. Metabolism (2007) 1.31
Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis (2002) 1.29
Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend (2007) 1.28
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med (2009) 1.23
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS (2004) 1.22
Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS (2004) 1.21
Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt) (2007) 1.20
Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.20
Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol (2011) 1.20
Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project. J Acquir Immune Defic Syndr (2002) 1.19
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS (2010) 1.19
Depressive symptoms in the immediate postpartum period among Hispanic women in three U.S. cities. J Immigr Health (2004) 1.19
Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS (2008) 1.18
Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS (2004) 1.18
Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS (2009) 1.17
Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2008) 1.17
Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS (2005) 1.17
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend (2005) 1.17
Longitudinal trends in hazardous alcohol consumption among women with human immunodeficiency virus infection, 1995-2006. Am J Epidemiol (2009) 1.16
The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr (2010) 1.15
Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse (2008) 1.14
Disclosure of complementary and alternative medicine use to health care providers among HIV-infected women. AIDS Patient Care STDS (2009) 1.14
The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis (2011) 1.13
The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther (2007) 1.13
A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health (2008) 1.13
Psychosocial characteristics and sexual behaviors of people in care for HIV infection: an examination of men who have sex with men, heterosexual men and women. AIDS Behav (2009) 1.12
Psychosocial and behavioral correlates of depression among HIV-infected pregnant women. AIDS Patient Care STDS (2004) 1.11